Analysts Set Owens & Minor, Inc. (NYSE:OMI) PT at $6.35

Owens & Minor, Inc. (NYSE:OMI) has earned a consensus recommendation of “Hold” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a sell recommendation, three have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $6.35.

A number of equities research analysts have issued reports on OMI shares. Robert W. Baird decreased their price objective on Owens & Minor from $10.00 to $7.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 12th. Zacks Research lowered Owens & Minor from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. Bank of America lowered their price target on Owens & Minor from $7.50 to $4.75 and set an “underperform” rating for the company in a research report on Tuesday, August 12th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Owens & Minor in a research report on Wednesday, October 8th. Finally, Citigroup reissued a “buy” rating and issued a $7.00 target price (down previously from $11.00) on shares of Owens & Minor in a research note on Tuesday, August 12th.

Owens & Minor Price Performance

OMI stock opened at $2.54 on Friday. Owens & Minor has a 52 week low of $2.45 and a 52 week high of $15.54. The firm has a market capitalization of $196.08 million, a P/E ratio of -0.15 and a beta of 1.37. The company has a fifty day simple moving average of $3.82 and a two-hundred day simple moving average of $5.69. The company has a quick ratio of 0.84, a current ratio of 0.86 and a debt-to-equity ratio of 3.32.

Owens & Minor (NYSE:OMI) last posted its earnings results on Thursday, October 30th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02. Owens & Minor had a negative net margin of 19.99% and a positive return on equity of 95.57%. The firm had revenue of $697.26 million for the quarter, compared to the consensus estimate of $704.06 million. During the same period in the previous year, the firm posted $0.36 EPS. The business’s quarterly revenue was up 1.5% on a year-over-year basis. Owens & Minor has set its FY 2025 guidance at 1.020-1.070 EPS. Analysts anticipate that Owens & Minor will post 1.51 earnings per share for the current fiscal year.

Institutional Trading of Owens & Minor

Several institutional investors have recently added to or reduced their stakes in OMI. Coliseum Capital Management LLC raised its position in Owens & Minor by 122.0% during the 1st quarter. Coliseum Capital Management LLC now owns 10,624,599 shares of the company’s stock valued at $95,940,000 after purchasing an additional 5,838,635 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Owens & Minor by 2.7% in the first quarter. Vanguard Group Inc. now owns 9,156,759 shares of the company’s stock valued at $82,686,000 after acquiring an additional 241,003 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Owens & Minor by 191.7% in the third quarter. Millennium Management LLC now owns 3,261,254 shares of the company’s stock valued at $15,654,000 after acquiring an additional 2,143,267 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Owens & Minor by 19.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,752,960 shares of the company’s stock worth $24,859,000 after acquiring an additional 447,917 shares during the period. Finally, Invenomic Capital Management LP bought a new position in Owens & Minor during the 3rd quarter worth about $13,196,000. Institutional investors own 98.04% of the company’s stock.

Owens & Minor Company Profile

Owens & Minor, Inc is a healthcare solutions company, which engages in the product manufacturing and delivery, home health supply, and perioperative services to support care through the hospital and into the home. It operates through the Products and Healthcare Services, and Patient Direct segments.